New-generation advanced PROTACs as potential therapeutic agents in cancer therapy

Proteolysis-targeting chimeras (PROTACs) technology has garnered significant attention over the last 10 years, representing a burgeoning therapeutic approach with the potential to address pathogenic proteins that have historically posed challenges for traditional small-molecule inhibitors. PROTACs exploit the endogenous E3 ubiquitin ligases to facilitate degradation of the proteins of interest (POIs) through the ubiquitin-proteasome system (UPS) in a cyclic catalytic manner. Despite recent endeavors to advance the utilization of PROTACs in clinical settings, the majority of PROTACs fail to progress beyond the preclinical phase of drug development. There are multiple factors impeding the market entry of…

• NN
  National Natural Science Foundation of China

  Award: 82303590
• CP
  China Postdoctoral Science Foundation

  Award: 2023M741867
• NS
  Natural Science Foundation of Shandong Province

  Award: ZR2021QH156
• NS
  Natural Science Foundation of Qingdao

  Award: 23-2-1-141-zyyd-jch